secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001493152-26-006081
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001
--------------------------------------------------------------------------------

- 100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).
- No viral rebounds observed during the 14-day post-treatment observation period.
- 16 of 38 subjects had non-detection by Day 5; 1 of 38 by Day 3.
- Phase 2 dose-optimization trial: randomized, double-blind, 38 subjects completed.
- Company plans regulatory discussions for late-stage development and additional viral indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226006081/0001493152-26-006081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315226006081/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer